| |
|
|
|
Hilton Back Bay, 40 Dalton Street, Boston, MA 02115
October 27-29, 2014
Several factors including diminishing financial return, lack of new discovery platforms and others, had a cooling effect on pharmaceutical companies' activity in the area of antibacterial drug development. At the same time, we are witnessing the wide spread of resistant bacteria, leading to untreatable infections. "We are facing a huge crisis worldwide not having an antibiotics pipeline," said Dr. Janet Woodcock, Director of CDER at FDA, in her recent interview to NYT. The governments of European countries and the United States have created several incentives for the industry to rise to the challenge. Therefore, many companies are exploring the opportunities to start or re-open their antibacterial departments, or to stimulate the existing research and development. Cambridge Healthtech Institute is pleased to present its inaugural Re-Entering Antibacterial Drug Development Summit that includes a science track and a business track, and features a wide range of pivotal issues. The Summit is designed as a forum for knowledge and opinion exchange between the major stakeholders shaping the current state of antibacterial discovery and development. CONFERENCE HIGHLIGHTS:
Targeting Key Antibacterial R&D Challenges (October 27-28) - Gram Negatives at The Top Of The Unmet Needs List
- Antibacterial Biologics
- The Bacterial Resistance Portfolio
- Sterilizing Antibiotics
- Technology To Serve Antibacterial R&D
Solving The Antibacterials Commercialization Equation (October 28-29) - Antibacterial Market Environment And Market Access Strategy
- Early Pricing Planning And Negotiations for A Product in Clinical Development
- Improving The Economics In The Antibiotic Market
- The Changing Landscape of Antibacterial Drug Development: The Role of Rapid Diagnostics
- Venture Capital Panel Discussion
Dinner Short Course (October 28): Funding Opportunities for Antibacterial Research |
|
|
|
|
|
|
|
Organized by:
|
|
Cambridge Healthtech Institute (CHI) |
|
|
Invited Speakers:
|
|
- Steven J. Projan, Ph.D., Senior Vice President, R&D, Innovative Medicines, Head, Infectious Disease & Vaccines MedImmune
- David C. Hooper, M.D., Professor of Medicine, Harvard Medical School; Chief, Infection Control Unit, Associate Chief, Division of Infectious Diseases, Massachusetts General Hospital
- James Brown, Ph.D., Director, Computational Biology (US), GSK
- Thomas M. Bocan, Ph.D., Molecular and Translational Sciences Division, US Army Medical Research Institute of Infectious Diseases
- Mark T. Esser, Ph.D., Director, Translational Medicine, Infectious Diseases and Vaccines, MedImmune
- Michael N. Dudley, Senior Vice President and CSO, Rempex Pharmaceuticals, now a wholly-owned subsidiary of The Medicines Company
- Alessandro Pini, Ph.D., Professor, Department of Medical Biotechnology, University of Siena
- Predrag Cudic, Ph.D., Assistant Member, Drug Discovery, Torrey Pines Institute for Molecular Studies
- Kim Lewis, Ph.D., University Distinguished Professor, Director, Antimicrobial Discovery Center, Department of Biology, Northeastern University
- Niren Murthy, Ph.D., Professor, Bioengineering, U.C. Berkeley
- Pieter Dorrestein, Ph.D., University of California - San Diego, Director, Therapeutic Discovery Mass Spectrometry Center, Co-Director, Institute for Metabolomics Medicine, Skaggs School of Pharmacy & Pharmaceutical Sciences, Departments of Pharmacology, Chemistry and Biochemistry
- Christopher-Paul Milne, Ph.D., Director, Research, Tufts CSDD, Tufts University School of Medicine
- Timothy D. Hunt, Senior Vice President, Public Affairs, Cubist Pharmaceuticals
- Carl Foster, Executive Vice President, Business Development, Cempra Pharmaceuticals
- Kevin Outterson, J.D., Professor, Law, Health Law, Bioethics and Human Rights, Boston University School of Law
- Linda A. Miller, Ph.D., Director, Diagnostics & Clinical Microbiology, Antibacterials R&D, Infectious Diseases Therapeutic Area Unit, GSK
- Prabhavathi Fernandes, Ph.D., President and CEO, Cempra, Inc.
- Barry Eisenstein, M.D., Senior Vice President, Scientific Affairs, Cubist Pharmaceuticals Editor, Antimicrobial Agents and Chemotherapy
- Melissa Stundick, Ph.D., Branch Chief, BARDA’s Broad Spectrum Antimicrobial Program
- Kleem Chaudhary, Ph.D., Director, Strategic Alliances, Novartis Institutes for BioMedical Research
- David Pompliano, Ph.D., Third Rock Ventures LLC
- Vikas Goyal, SR One
- Kush M. Parmar, M.D., Ph.D., 5AM Ventures
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
---
|
|
|
|
|
|
|
|
Registration:
|
|
Register Now
|
|
|
E-mail:
|
|
kwaterman@healthtech.com
|
|
|
|
|
|
|
|
|